{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subcutaneous+Fat+Disorder&page=2",
    "query": {
      "condition": "Subcutaneous Fat Disorder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subcutaneous+Fat+Disorder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T02:03:40.890Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03233841",
      "title": "Farber Disease Natural History Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Farber Disease",
        "Farber's Disease",
        "Farber Lipogranulomatosis",
        "Acid Ceramidase Deficiency",
        "Ceramidase Deficiency",
        "N-Laurylsphingosine Deacylase Deficiency",
        "ASAH1 Mutation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 45,
      "start_date": "2017-11-22",
      "completion_date": "2019-12-09",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233841"
    },
    {
      "nct_id": "NCT03700827",
      "title": "Effects of Aerobic and Resistance Training on Abdominal Fat Loss",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity, Abdominal"
      ],
      "interventions": [
        {
          "name": "Resistance Training",
          "type": "OTHER"
        },
        {
          "name": "Aerobic Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Southern Illinois University Edwardsville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2017-10-01",
      "completion_date": "2020-05-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-04",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 1,
      "location_summary": "Edwardsville, Illinois",
      "locations": [
        {
          "city": "Edwardsville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03700827"
    },
    {
      "nct_id": "NCT02907411",
      "title": "Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lipedema"
      ],
      "interventions": [
        {
          "name": "Quadrivas Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 70 Years · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2016-09-01",
      "completion_date": "2017-03-18",
      "has_results": false,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02907411"
    },
    {
      "nct_id": "NCT04708535",
      "title": "Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Insulin Resistance",
        "Insulin Sensitivity",
        "Obesity",
        "Inflammation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-08-01",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708535"
    },
    {
      "nct_id": "NCT02596776",
      "title": "Cold Induced Changes in White Adipose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Obese",
        "Normal Body Weight",
        "Prediabetes",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Fat biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Propranolol and fat biopsy",
          "type": "DRUG"
        },
        {
          "name": "heavy water and fat biopsy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 60 Years · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2016-03",
      "completion_date": "2018-08-20",
      "has_results": false,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02596776"
    },
    {
      "nct_id": "NCT02115724",
      "title": "Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Antioxidant cocktail",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Biopsy",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "NMD; 0.4mg sub-lingual nitroglycerin spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 74,
      "start_date": "2014-04",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115724"
    },
    {
      "nct_id": "NCT07220785",
      "title": "Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Mibavademab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2026-03-13",
      "completion_date": "2028-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220785"
    },
    {
      "nct_id": "NCT06548100",
      "title": "A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "mibavademab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-12-16",
      "completion_date": "2026-11-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06548100"
    },
    {
      "nct_id": "NCT01448239",
      "title": "Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "alirocumab SAR236553 (REGN727)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-28",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448239"
    },
    {
      "nct_id": "NCT06679270",
      "title": "Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Partial Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Metreleptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amryt Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-10-14",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-06-27T02:03:40.890Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbour",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679270"
    }
  ]
}